EF5 in Treating Patients With Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

Diagnostic procedures using the drug EF5 to detect the presence of oxygen in tumor cells may help to plan effective treatment for solid tumors. This phase I trial is studying how well EF5 works in detecting the presence of oxygen in tumor cells in patients with solid tumors that can be biopsied or removed by surgery

Key facts

Study ID

NCT00003282

Run by

National Cancer Institute (NCI)

People needed

50

Starts

1998-03-01

Last updated by the study team

2013-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologically confirmed tumor or highly suspicious cancerous mass based on imaging and clinical signs but not indicative of a direct biopsy/cellular diagnosis preceding surgery
• Must have a clinical condition or physiologic status which demonstrates that the appropriate or standard initial therapy for the tumor is surgical biopsy or resection
• Performance status - ECOG 0-2
• Life expectancy not specified
• WBC greater than 2,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Bilirubin less than 2.0 mg/dL
• Creatinine less than 2.0 mg/dL
• Creatinine clearance greater than 50 mL/min
• No significant cardiac disease that would preclude the safe use of general anesthesia
• No significant pulmonary disease that would preclude the safe use of general anesthesia
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 month after study
• No history of grade III or IV peripheral neuropathy
• See Disease Characteristics

Where it is running

• Abramson Cancer Center of The University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.